文献速递泌尿男性生殖肿瘤

活检分级分组1级前列腺癌按活检分级和风险分组的结局

Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group.
PubMed 文献 · JAMA Oncol · 2025-01-01

这项基于监测、流行病学和最终结果(SEER)数据的队列研究纳入117 162例局部分级分组1级(GG1)前列腺癌男性,按美国国家综合癌症网络(NCCN)风险组分层,评估前列腺癌特异性死亡和根治术后不良病理。约1/6患者为中危或高危,高危GG1中60%根治术后有不良病理,GG1长期结局异质,并非均呈惰性。

要点

  • 117 162例活检GG1前列腺癌中,9%为预后良好中危、3%为预后不良中危、4%为高危。
  • 高危GG1中867例(60%)根治术后存在不良病理。
  • 预后不良中危GG1和高危GG1的前列腺癌特异性死亡率分别为2.4%和4.7%。

核心结论

  • 约1/6活检GG1前列腺癌患者为中危或高危疾病,GG1长期结局异质,并非所有GG1均呈惰性病程。
  • 部分活检GG1患者结局与更高分级中危前列腺癌相当,后者常接受治疗,这些发现应纳入GG1重新分类讨论。

研究设计与样本

  • 基于监测、流行病学和最终结果(SEER)数据的基于人群的队列研究。
  • 纳入2010年1月1日至2020年12月31日117 162例局部GG1前列腺癌男性,按美国国家综合癌症网络(NCCN)风险组分层。
  • 采用竞争风险分析和多变量回归评估前列腺癌特异性死亡率和根治术后不良病理关联;数据分析时间为2024年7月1日至2024年10月1日。

主要发现

  • 117 162例活检GG1前列腺癌中,10 440例(9%)为预后良好中危,3145例(3%)为预后不良中危,4539例(4%)为高危;中位年龄64岁(IQR,58-69岁)。
  • 高危GG1前列腺癌中867例(60%)根治术后存在不良病理。
  • 预后不良中危GG1和高危GG1的前列腺癌特异性死亡率分别为2.4%和4.7%,与预后良好中危GG2(2.1%)和预后不良中危≥GG2(4.0%)相当。
  • 校正分析中,与低危GG1相比,预后良好中危GG1(校正风险比[AHR],1.60;95%CI,1.30-1.96)、预后不良中危GG1(AHR,2.10;95%CI,1.53-2.89)和高危GG1(AHR,3.58;95%CI,2.93-4.38)与前列腺癌特异性死亡风险增加相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Advocates for removing the cancer label from grade group 1 (GG1) prostate cancer detected on biopsy primarily base their argument on the observation that when only GG1 is detected on prostatectomy, rates of metastasis are rare. However, the frequency with which GG1 prostate cancer on biopsy is associated with adverse clinical features and the long-term cancer outcomes in this context are poorly defined. OBJECTIVE: To assess cancer-specific outcomes of localized GG1 prostate cancer stratified by risk category. DESIGN, SETTING, AND PARTICIPANTS: A population-based cohort study using Surveillance, Epidemiology, and End Results data was performed to assess cancer-specific outcomes in 117 162 men with localized GG1 prostate cancer stratified by National Comprehensive Cancer Network risk groups between January 1, 2010, and December 31, 2020. Competing risk analyses and multivariable regression determined rates of prostate cancer-specific mortality and associations with prostatectomy adverse pathology. Data were analyzed from July 1, 2024, to October 1, 2024. MAIN OUTCOMES: Prostate cancer-specific mortality and risk of adverse pathology at surgery in GG1 prostate cancer. RESULTS: Among 117 162 men with biopsy GG1 prostate cancer, 10 440 (9%) had favorable intermediate-risk disease, 3145 (3%) had unfavorable intermediate-risk disease, and 4539 (4%) had high-risk disease. Median age was 64 years (IQR, 58-69 years). A total of 867 men with high-risk GG1 prostate cancer (60%) had adverse pathology at prostatectomy. The prostate cancer-specific mortality rates for unfavorable intermediate-risk GG1 and for high-risk GG1 were 2.4% and 4.7%, respectively, comparable to the prostate cancer-specific mortality rates for favorable intermediate-risk GG2 and unfavorable intermediate-risk greater than or equal to GG2, which were 2.1% and 4.0%, respectively. In adjusted analyses, favorable intermediate-risk GG1 (adjusted hazard ratio [AHR], 1.60; 95% CI, 1.30-1.96), unfavorable intermediate-risk GG1 (AHR, 2.10; 95% CI, 1.53-2.89), and high-risk GG1 (AHR, 3.58; 95% CI, 2.93-4.38) were associated with increased risk of prostate cancer-specific mortality compared with low-risk GG1. CONCLUSIONS AND RELEVANCE: This cohort study found that approximately 1 in 6 men with GG1 prostate cancer has intermediate-risk or high-risk disease. Biopsy GG1 prostate cancer has heterogeneous long-term outcomes that are reflected in adverse pathology and prostate cancer-specific mortality. These data indicate that not all GG1 prostate cancer follows an indolent course. A subset of men with biopsy GG1 prostate cancer have outcomes comparable to those of men with higher-grade intermediate-risk prostate cancer, a group that often undergoes treatment. These findings should be considered in the reclassification debate.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Patel NA, Barocas DA, Lin DW, et al. Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group. JAMA Oncol. 2025. PMID: 40742601. doi:10.1001/jamaoncol.2025.2304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。